|
22 Jan 2020 |
News |
QD Clinic - Hepatitis B and Biologics |
|
|
21 Jan 2020 |
News |
Biosimilars for Rheum Disease: Failure to Launch |
|
|
17 Jan 2020 |
Social |
Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/3EI52M5kIR |
|
|
02 Jan 2020 |
News |
Best of 2019 - Is Methotrexate Necessary with Tofacitinib? |
|
|
01 Jan 2020 |
Social |
Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb |
|
|
31 Dec 2019 |
News |
Best of 2019 - Ups and Downs with Abatacept |
|
|
30 Dec 2019 |
News |
Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors? |
|
|
26 Dec 2019 |
News |
Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots |
|
|
25 Dec 2019 |
News |
Best of 2019 - Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis |
|
|
23 Dec 2019 |
News |
Gilead Submits Filgotinib NDA to the FDA |
|
|
16 Dec 2019 |
Social |
FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers. https://t.co/L9lcHfosU1 |
|
|
11 Dec 2019 |
Social |
Biosimilar Tote-Board in Rheumatology:
4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola
5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada
2 Etanercept biosimilars - Erelzi, Enticovo
2 Rituximab biosimilars - Truxima, Ruxience |
|
|
11 Dec 2019 |
Social |
FDA has approved Amgen’s infliximab biosimilar, Avsola (infliximab-axxq),for use in Crohns, UC, RA, AS, PsA and psoriasis, based on a 566 pt trial in RA. This is the 4th infliximab biosimilar in the US, joining Inflectra, Renflexis, and Ixifi. https://t.co/nFhyMM1OnK |
|
|
10 Dec 2019 |
News |
Variations in First Biologic Use in Rheumatoid Arthritis |
|
|
10 Dec 2019 |
Social |
BEST JOURNAL TITLE OF THE WK - "The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis." https://t.co/9ncBmDbd6B |
|
|
28 Nov 2019 |
Social |
RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ… |
|
|
26 Nov 2019 |
Social |
The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA). https://t.co/cJFEk464Wr |
|
|
26 Nov 2019 |
News |
BMS and Celgene Merge as Amgen Buys Otezla |
|
|
21 Nov 2019 |
Social |
FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT |
|
|
20 Nov 2019 |
News |
ACR 2019 – Best of the Plenary Sessions |
|
